FY results 2024

Positioned for strong growth

FY 2024 documents

Market leader in peptide API manufacturing and services

PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API). 

Media releases

PolyPeptide announces results of the annual General Meeting 2025

9 Apr 2025 - Baar, 9 April 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]

Read more
Expert views

Expanding the Reach of Sustainable Solid-Phase Peptide Synthesis

2 Apr 2025 - Alloc protecting group expanded the peptide synthesis toolbox. Its removal can sometimes be seen as an issue: toxic solvents, air-sensitive Pd0) reagents, challenging upscaling. Not anymore […]

Read more

PolyPeptide video

PolyPeptide Group - Ahead on green peptide chemistry